Search results
AstraZeneca pulls its COVID-19 vaccine from Europe
Boston Herald· 5 days agoAstraZeneca’s COVID-19 vaccine was first given the nod by the EMA in January 2021.
Moderna says FDA will not complete review of RSV vaccine by May 12 deadline
Market Watch· 4 days agoThe FDA cited administrative constraints for the delay, Cambridge, Mass.-based Moderna said in a...
Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
CNBC· 1 day agoA vial labelled "Novavax V COVID-19 Vaccine" is seen in this illustration taken January 16, 2022....
Moderna's RSV Vaccine Approval Faces Setback as FDA Delays Decision
Homenewshere.com· 4 days agoModerna announced that the FDA had delayed approval of its RSV vaccine to the end of May due to...
Moderna Announces Update on Investigational RSV Vaccine
Morningstar· 4 days agoThe FDA has informed Moderna that it is working to conclude...
AstraZeneca withdraws Covid-19 vaccine, citing low demand | CNN Business
CNN.com· 6 days agoThe vaccine — called Vaxzevria and developed in partnership with the University of Oxford — has been...
AstraZeneca pulls its COVID-19 vaccine from the European market
Atlanta Journal-Constitution· 6 days agoAstraZeneca's COVID-19 vaccine was first given the nod by the EMA in January 2021.
AstraZeneca pulls its COVID-19 vaccine from the European market
Stamford Advocate· 6 days agoAstraZeneca's COVID-19 vaccine was first given the nod by the EMA in January 2021. Within weeks,...
AstraZeneca pulls COVID-19 vaccine from global markets
UPI· 6 days agoAstraZeneca Wednesday said it was pulling its Vaxzevria COVID-19 vaccine pictured here from sale...
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher? | The Motley Fool
The Motley Fool· 11 hours agoThe market was responding to terrific news from Sanofi (NASDAQ: SNY), a global pharmaceutical giant...